Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CYCLOPHOSPHAMIDE

2 general benefit · 1 not a benefit

Other products in the same Health Canada class (L01A, L01AA) — coverage varies; not interchangeable

  • Chlorambucil (Leukeran): general benefit
  • Melphalan (Alkeran): general benefit
  • Busulfan (Myleran): general benefit
  • Lomustine ccnu (Gleostine): general benefit, Listing status unconfirmed
  • Temozolomide (Temodal): general benefit

Procytox · DIN 02241795 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Procytox · DIN 02241795 Manufacturer: Baxter Corporation; listing date 2005-05-25 Health Canada: Marketed since 2003-10-03 · brand PROCYTOX · ATC L01AA01 CYCLOPHOSPHAMIDE · form Tablet · route Oral · ingredients CYCLOPHOSPHAMIDE 25 MG · company Baxter corporation · schedule Prescription
Check this DIN again · Health Canada product record

Procytox: Formulary list price $0.3545/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3545 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65460 · Verify on the e-Formulary ↗ (DIN 02241795)

Source record
DIN 02241795: Procytox Raw flags: sec3=Y Item: 100000008; group id 151; item number 0255; lccId None; manufacturer id BAX Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.3545; ministry $0.3545 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241795 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65460
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241795
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Procytox · DIN 02241796 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Procytox · DIN 02241796 Manufacturer: Baxter Corporation; listing date 2005-05-25 Health Canada: Marketed since 2003-09-09 · brand PROCYTOX · ATC L01AA01 CYCLOPHOSPHAMIDE · form Tablet · route Oral · ingredients CYCLOPHOSPHAMIDE 50 MG · company Baxter corporation · schedule Prescription
Check this DIN again · Health Canada product record

Procytox: Formulary list price $0.4773/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65461 · Verify on the e-Formulary ↗ (DIN 02241796)

Source record
DIN 02241796: Procytox Raw flags: sec3=Y Item: 100000007; group id 151; item number 0256; lccId None; manufacturer id BAX Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.4773; ministry $0.4773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65461
Interchangeable products
Cytoxan · DIN 00344885 · not recorded
Shortage status: resolved shortage (ended 2025-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241796
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cytoxan · DIN 00344885 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-01-22 — choose a marketed DIN from the same-category list.Discontinued 2009-01-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-01-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cytoxan · DIN 00344885 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2009-01-22 · brand CYTOXAN TAB 50MG · ATC L01AA01 CYCLOPHOSPHAMIDE · form Tablet · route Oral · ingredients CYCLOPHOSPHAMIDE 50 MG · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Cytoxan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2403 · Verify on the e-Formulary ↗ (DIN 00344885)

Source record
DIN 00344885: Cytoxan Raw flags: notABenefit=Y, sec3=Y Item: 100000007; group id 151; item number 0256; lccId None; manufacturer id BQU Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00344885 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2403
Interchangeable products
Procytox · DIN 02241796 · $0.4773
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00344885
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-01-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

MELPHALAN

· 1 products · General benefit · strengths: 2mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

LOMUSTINE (CCNU)

· 5 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (1) · strengths: 10mg, 40mg, 100mg · Cap

TEMOZOLOMIDE

· 20 products · General benefit · strengths: 5mg, 20mg, 100mg, 140mg, 250mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE PROCYTOX (Cyclophosphamide), used alone or as a component of combination therapy is indicated for: A: Frequently responsive myeloproliferative and lymphoproliferative disorders 1. Malignant lymphomas (See also DOSAGE AND ADMINISTRATION) a) Hodgkin's disease [Cotswold stages II & III (massive mediastinal disease) and IIIA1,2 - IV E] Non-Hodgkin's lymphomas (Working Formulation. Low Grade A,B,C; Intermediate Grade D,E,F,G; High Grade H,I,J) b) Follicular lymphoma (B,C,D) c) Lymphocytic lymphoma (A,B,E; mixed histiocytic, C,F) ** Note: Type A, small diffuse and well differentiated malignant lymphocytic lymphoma is consistent with chronic lymphocytic leukemia, to be considered a heterogenous group of chronic B-cell disorders. d) Diffuse histiocytic lymphoma (G,H) e) Lymphoblastic lymphoma (I) f) Burkitt's lymphoma (J) PROCYTOX (Cyclophosphamide) … https://pdf.hres.ca/dpd_pm/00017604.PDF PM date: not printed or not captured Source product: PROCYTOX; DIN 02241795; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Procytox · DIN 02241795 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241795

Check this DIN again

Other review policies

For Cytoxan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026